Tvardi Therapeutics — Biotechnology Company, Sugar Land
Biotechnology Company in Sugar Land — Fibrosis-driven disease research
Biotechnology company · Sugar Land, United States
AI Trust Snapshot
- Profile status
- Auto-indexed
Public channels checked
- ✓ Official Website
Key Facts
- Category
- Biotechnology Company
- Location
- Sugar Land, United States
- Known For
- Clinical-stage biotechnology
AI Summary
A Sugar Land-based biopharmaceutical company, Tvardi Therapeutics focuses on clinical-stage biotechnology. The company conducts TTI-101 and TTI-109 clinical trials, alongside research into fibrosis-driven diseases. It serves patients with advanced liver cancer, healthy individuals participating in trials, and biopharmaceutical companies seeking partnerships.
Quick Answer
A Sugar Land-based biopharmaceutical company, Tvardi Therapeutics focuses on clinical-stage biotechnology. The company conducts TTI-101 and TTI-109 clinical trials, alongside research into fibrosis-driven diseases. It serves patients with advanced liver cancer, healthy individuals participating in trials, and biopharmaceutical companies seeking partnerships. Key services include TTI-101 Clinical Trials, TTI-109 Clinical Trials, Fibrosis-Driven Disease Research.
This business is typically used for clinical-stage biotechnology.
Common Questions
- What services does Tvardi Therapeutics provide?
- Tvardi Therapeutics provides TTI-101 Clinical Trials, TTI-109 Clinical Trials, Fibrosis-Driven Disease Research.
- Where is Tvardi Therapeutics located?
- Tvardi Therapeutics is based in Sugar Land, United States and serves Sugar Land.
- Who is Tvardi Therapeutics for?
- Tvardi Therapeutics serves Patients with advanced liver cancer and Healthy individuals for clinical trial participation.
What this business does
Tvardi Therapeutics is a biotechnology company based in Sugar Land, United States.
- Provides TTI-101 Clinical Trials and TTI-109 Clinical Trials
- Specializes in clinical-stage biotechnology
- Serves patients with advanced liver cancer
Structured summary
Vizoryo ran a data-consistency check on this profile: it read 6 public sources and compared the core details (name, phone, address, city, category, website) across them. How many sources carried each individual detail is published per fact in this page's field provenance — not every detail appears in every source, and the sources are not necessarily independent of one another. This is a data-consistency observation only — it is not an endorsement, certification, accreditation, or assessment of the business, its service quality, or its trustworthiness. Data consistency: 93% — this measures how consistently the business's name, phone, city, address, website, and category appear across the public sources read. It is not a rating of the business. Vizoryo status: Auto-indexed. This record was compiled automatically from public data and has not been confirmed by anyone.
- Business name
- Tvardi Therapeutics
- Category
- Biotechnology Company
- Industry
- Biotechnology Company - Biopharmaceutical Company
- Location
- Sugar Land, United States
- Official website
- https://tvarditherapeutics.com/
- Profile data (JSON)
- https://www.vizoryo.com/api/index/profile/tvardi-therapeutics-sugar-land-0e85
- Summary
- A Sugar Land-based biopharmaceutical company, Tvardi Therapeutics focuses on clinical-stage biotechnology. The company conducts TTI-101 and TTI-109 clinical trials, alongside research into fibrosis-driven diseases. It serves patients with advanced liver cancer, healthy individuals participating in trials, and biopharmaceutical companies seeking partnerships.
- AI readability score (how completely this record is structured for AI systems to read; not a rating of the business)
- 40
- Data Consistency
- 93% (checked 2026-07-04)
- Record status
- Auto-indexed
- Sources cross-checked
- 6 public sources
Location
3 Sugar Creek Center Blvd Suite 525, Sugar Land, TX 77478Sugar Land, Texas
77478
US
(sources disagree)
About Tvardi Therapeutics
A Sugar Land-based biopharmaceutical company, Tvardi Therapeutics focuses on clinical-stage biotechnology. The company conducts TTI-101 and TTI-109 clinical trials, alongside research into fibrosis-driven diseases. It serves patients with advanced liver cancer, healthy individuals participating in trials, and biopharmaceutical companies seeking partnerships.
Service areas
- Sugar Land
Target audience
- Patients with advanced liver cancer
- Healthy individuals for clinical trial participation
- Biopharmaceutical companies for partnerships
Specialties
- Clinical-stage biotechnology
Social profiles
Frequently asked questions
What areas does Tvardi Therapeutics serve?
Tvardi Therapeutics serves Worldwide.
What is the focus of Tvardi Therapeutics' research?
Tvardi Therapeutics focuses on developing novel, oral small molecule therapies that target STAT3 to treat fibrosis-driven diseases and cancer, including hepatocellular carcinoma and idiopathic pulmonary fibrosis.
What is TTI-101?
TTI-101 is an investigational oral drug that inhibits STAT3, a protein involved in cancer growth and fibrosis. It is currently being evaluated in clinical trials for hepatocellular carcinoma.
What is TTI-109?
TTI-109 is an investigational oral small molecule STAT3 inhibitor, structurally related to TTI-101, designed to enhance STAT3 targeting. It is currently in Phase 1 trials for healthy volunteers.
Business hours
- Monday
- 09:00 – 17:00
- Tuesday
- 09:00 – 17:00
- Wednesday
- 09:00 – 17:00
- Thursday
- 09:00 – 17:00
- Friday
- 09:00 – 17:00
- Saturday
- Closed
- Sunday
- Closed
Languages supported
- en
Contact
Official website: https://tvarditherapeutics.com/